|
CN105367503A
(zh)
|
2007-10-19 |
2016-03-02 |
阿维拉制药公司 |
杂芳基化合物和其用途
|
|
US7989465B2
(en)
*
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
PT2300013T
(pt)
|
2008-05-21 |
2017-10-31 |
Ariad Pharma Inc |
Derivados de fósforo como inibidores de cinases
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
TWI546290B
(zh)
|
2008-06-27 |
2016-08-21 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Ｅｇｆｒ 억제제 및 질환 치료방법
|
|
AR076550A1
(es)
*
|
2009-05-06 |
2011-06-22 |
Portola Pharm Inc |
Inhibidores de la janus tirosina kinasa (jak)
|
|
EP2440204B1
(en)
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
|
NZ620174A
(en)
|
2009-09-16 |
2016-08-26 |
Celgene Avilomics Res Inc |
Protein kinase conjugates and inhibitors
|
|
US8466155B2
(en)
*
|
2009-10-02 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Pyrimidines
|
|
EP2519664A4
(en)
|
2009-12-30 |
2014-03-12 |
Avila Therapeutics Inc |
LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
|
|
WO2011146313A1
(en)
|
2010-05-19 |
2011-11-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
US8927547B2
(en)
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
|
PT2576541T
(pt)
|
2010-06-04 |
2016-07-08 |
Hoffmann La Roche |
Derivados de aminopirimidina como moduladores de lrrk2
|
|
CN105566229A
(zh)
|
2010-08-10 |
2016-05-11 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐及其用途和制备方法
|
|
MX382354B
(es)
|
2010-11-01 |
2025-03-13 |
Celgene Car Llc |
Compuestos heterocíclicos y usos de los mismos.
|
|
EP2635285B1
(en)
|
2010-11-01 |
2017-05-03 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
HRP20172006T1
(hr)
|
2010-11-10 |
2018-02-09 |
Genentech, Inc. |
Derivati pirazol-aminopiridina kao lrrk2-modulatori
|
|
JP5957003B2
(ja)
|
2010-11-10 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
変異体選択的ｅｇｆｒ阻害剤およびその使用
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
DK2688883T3
(en)
|
2011-03-24 |
2016-09-05 |
Noviga Res Ab |
pyrimidine
|
|
BR112013025387B1
(pt)
|
2011-04-01 |
2021-07-27 |
University Of Utah Research Foundation |
Compostos análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl, uso dos ditos compostos para o tratamento de um distúrbio de proliferação celular descontrolada, bem como kit compreendendo ditos compostos
|
|
EP2694486B1
(en)
|
2011-04-01 |
2018-01-10 |
University of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
SMT202400031T1
(it)
|
2011-04-22 |
2024-03-13 |
Signal Pharm Llc |
Diamminocarbossammide e diamminocarbonitrile pirimidine sostituite, loro composizioni e metodi di trattamento con esse
|
|
WO2012148994A1
(en)
|
2011-04-25 |
2012-11-01 |
Usher Iii Initiative |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
US9834518B2
(en)
|
2011-05-04 |
2017-12-05 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
|
CN103702990B
(zh)
|
2011-07-27 |
2015-09-09 |
阿斯利康(瑞典)有限公司 |
2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
|
|
BR112014007788A2
(pt)
|
2011-10-03 |
2017-04-18 |
Univ North Carolina Chapel Hill |
compostos de pirrolopirimidina para tratamento do câncer
|
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
|
US9464089B2
(en)
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
CA2861010A1
(en)
|
2012-01-13 |
2013-07-18 |
Xiao Xu |
Heterocyclic compounds and uses as anticancer agents
|
|
PL2805940T3
(pl)
|
2012-01-17 |
2017-06-30 |
Astellas Pharma Inc. |
Związek pirazynokarboksyamidowy
|
|
PL2825042T3
(pl)
|
2012-03-15 |
2019-02-28 |
Celgene Car Llc |
Sole inhibitora kinazy receptora czynnika wzrostu naskórka
|
|
KR102081042B1
(ko)
*
|
2012-03-15 |
2020-02-26 |
셀젠 카르 엘엘씨 |
상피 성장 인자 수용체 키나제 억제제의 고체 형태
|
|
US20150166591A1
(en)
|
2012-05-05 |
2015-06-18 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for raf kinase mediated diseases
|
|
WO2013173518A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
CN104302627A
(zh)
|
2012-05-22 |
2015-01-21 |
北卡罗来纳大学教堂山分校 |
用于治疗癌症的嘧啶化合物
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US20150216865A1
(en)
*
|
2012-09-04 |
2015-08-06 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
US9296703B2
(en)
|
2012-10-04 |
2016-03-29 |
University Of Utah Research Foundation |
Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
|
|
WO2014055928A2
(en)
*
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
WO2014062774A1
(en)
|
2012-10-17 |
2014-04-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
US8765762B2
(en)
|
2012-10-25 |
2014-07-01 |
Usher III, Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
|
|
US9227976B2
(en)
|
2012-10-25 |
2016-01-05 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
EP2922826A4
(en)
*
|
2012-11-20 |
2016-08-03 |
Celgene Avilomics Res Inc |
METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE
|
|
TW201427667A
(zh)
*
|
2012-11-20 |
2014-07-16 |
Celgene Avilomics Res Inc |
治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法
|
|
US20140142128A1
(en)
*
|
2012-11-20 |
2014-05-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
WO2014081714A2
(en)
*
|
2012-11-20 |
2014-05-30 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
US9771330B2
(en)
|
2012-11-27 |
2017-09-26 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CA2899281C
(en)
|
2013-01-25 |
2022-05-31 |
Rigel Pharmaceuticals, Inc. |
Pyrimidinediamine compounds for use in treating or preventing autoimmune alopecia
|
|
AU2014214846A1
(en)
*
|
2013-02-08 |
2015-07-23 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
|
WO2014130856A2
(en)
*
|
2013-02-21 |
2014-08-28 |
Wayne Rothbaum |
Treatment of skeletal-related disorders
|
|
AR094929A1
(es)
|
2013-02-28 |
2015-09-09 |
Bristol Myers Squibb Co |
Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
|
|
WO2014134391A1
(en)
|
2013-02-28 |
2014-09-04 |
Bristol-Myers Squibb Company |
Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
HRP20170217T1
(hr)
|
2013-04-25 |
2017-04-21 |
Beigene, Ltd. |
Fuzinirani heterociklički spojevi kao inhibitori protein kinaze
|
|
US20160074399A1
(en)
*
|
2013-05-06 |
2016-03-17 |
Clovis Oncology, Inc. |
Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
|
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
|
JP6509838B2
(ja)
|
2013-06-26 |
2019-05-08 |
アッヴィ・インコーポレイテッド |
Ｂｔｋ阻害薬としての一級カルボキサミド類
|
|
CN105377835B
(zh)
*
|
2013-07-11 |
2018-08-17 |
贝达药业股份有限公司 |
酪氨酸蛋白激酶调节剂及其应用方法
|
|
NZ715687A
(en)
*
|
2013-07-11 |
2019-04-26 |
Acea Biosciences Inc |
Pyrimidine derivatives as kinase inhibitors
|
|
KR101828187B1
(ko)
|
2013-08-12 |
2018-02-09 |
다이호야쿠힌고교 가부시키가이샤 |
신규 축합 피리미딘 화합물 또는 그 염
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
WO2015039613A1
(zh)
*
|
2013-09-18 |
2015-03-26 |
北京韩美药品有限公司 |
抑制btk和/或jak3激酶活性的化合物
|
|
BR112016008632A8
(pt)
|
2013-10-21 |
2020-03-17 |
Merck Patent Gmbh |
compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
|
|
US9795604B2
(en)
|
2013-10-25 |
2017-10-24 |
Pharmacyclics Llc |
Methods of treating and preventing graft versus host disease
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
NZ715903A
(en)
|
2014-01-30 |
2017-06-30 |
Signal Pharm Llc |
Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
|
|
US11039620B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US9622483B2
(en)
|
2014-02-19 |
2017-04-18 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US11039621B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
CN104860941B
(zh)
*
|
2014-02-25 |
2017-03-22 |
上海海雁医药科技有限公司 |
2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
|
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
US20170173011A1
(en)
*
|
2014-03-07 |
2017-06-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
US20150291606A1
(en)
|
2014-04-11 |
2015-10-15 |
The University Of North Carolina At Chapel Hill |
Mertk-specific pyrrolopyrimidine compounds
|
|
EP3144292B1
(en)
|
2014-04-14 |
2020-08-26 |
Shanghai Haiyan Pharmaceutical Technology Co., Ltd |
2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
|
|
JP2017514805A
(ja)
*
|
2014-04-16 |
2017-06-08 |
シグナル ファーマシューティカルズ，エルエルシー |
Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
|
|
US10300058B2
(en)
|
2014-04-18 |
2019-05-28 |
Xuanzhu Pharma Co., Ltd. |
Tyrosine kinase inhibitor and uses thereof
|
|
CN104130265B
(zh)
*
|
2014-04-29 |
2017-01-25 |
苏州景泓生物技术有限公司 |
一种含有螺环或桥环的嘧啶类化合物
|
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
CN105315285B
(zh)
*
|
2014-07-25 |
2017-12-08 |
上海海雁医药科技有限公司 |
2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
|
|
HRP20220522T1
(hr)
|
2014-08-04 |
2022-06-10 |
Nuevolution A/S |
Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
|
|
EP4578865A3
(en)
|
2014-08-12 |
2025-07-30 |
Monash University |
Lymph directing prodrugs
|
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
|
DK3185868T3
(da)
|
2014-08-25 |
2022-05-23 |
Salk Inst For Biological Studi |
Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
|
|
CN105399686B
(zh)
*
|
2014-09-16 |
2018-05-22 |
深圳微芯生物科技有限责任公司 |
嘧啶衍生物、其制备方法及其应用
|
|
CN105481778B
(zh)
*
|
2014-09-16 |
2019-06-04 |
深圳微芯生物科技股份有限公司 |
嘧啶衍生物、其制备方法及其应用
|
|
CN105399685B
(zh)
*
|
2014-09-16 |
2018-05-22 |
深圳微芯生物科技有限责任公司 |
作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用
|
|
RS62017B1
(sr)
|
2014-09-17 |
2021-07-30 |
Celgene Car Llc |
Mk2 inhibitori i njihova upotreba
|
|
CN117069700B
(zh)
*
|
2014-10-11 |
2026-01-30 |
上海翰森生物医药科技有限公司 |
Egfr抑制剂及其制备和应用
|
|
EP3206691B1
(en)
|
2014-10-14 |
2018-09-19 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
JP6882978B2
(ja)
|
2014-10-29 |
2021-06-02 |
バイスクルアールディー・リミテッド |
Ｍｔ１−ｍｍｐに特異的な二環性ペプチドリガンド
|
|
CN105601573B
(zh)
*
|
2014-11-24 |
2021-07-02 |
中国科学院上海药物研究所 |
2-氨基嘧啶类化合物及其药物组合物和应用
|
|
AU2015360547A1
(en)
*
|
2014-12-11 |
2017-06-01 |
Merck Patent Gmbh |
Assays for BTK inhibitors
|
|
BR112017012795A2
(pt)
|
2014-12-16 |
2018-01-02 |
Signal Pharmaceuticals, Llc |
Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida
|
|
EP3233808B1
(en)
|
2014-12-16 |
2021-07-14 |
Signal Pharmaceuticals, LLC |
Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
|
|
WO2016123291A1
(en)
|
2015-01-29 |
2016-08-04 |
Signal Pharmaceuticals, Llc |
Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
|
|
KR101852738B1
(ko)
|
2015-01-30 |
2018-04-27 |
다이호야쿠힌고교 가부시키가이샤 |
축합 피리미딘 화합물의 신규한 염 및 그 결정
|
|
TWI638817B
(zh)
*
|
2015-01-30 |
2018-10-21 |
大鵬藥品工業股份有限公司 |
免疫疾病之預防及／或治療劑
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
EP3262049B1
(en)
|
2015-02-27 |
2022-07-20 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
CN108137559B
(zh)
*
|
2015-07-09 |
2021-11-02 |
默克专利有限公司 |
用作btk抑制剂的嘧啶衍生物及其用途
|
|
CA3208587A1
(en)
|
2015-07-24 |
2017-02-02 |
Celgene Corporation |
Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
|
|
AU2016317049A1
(en)
|
2015-08-31 |
2018-03-15 |
Pharmacyclics Llc |
BTK inhibitor combinations for treating multiple myeloma
|
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
CA2997106C
(en)
|
2015-09-08 |
2024-06-04 |
Monash University |
Lymph directing prodrugs
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
EA201890730A1
(ru)
|
2015-09-16 |
2018-10-31 |
Локсо Онколоджи, Инк. |
Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
|
|
CN106554347B
(zh)
*
|
2015-09-25 |
2020-10-30 |
浙江博生医药有限公司 |
Egfr激酶抑制剂及其制备方法和应用
|
|
KR20180067584A
(ko)
|
2015-10-09 |
2018-06-20 |
아세아 테라퓨틱스 인코포레이티드 |
피롤로피리미딘 키나아제 억제제의 약학적 염, 물리적 형태 및 조성물, 및 이들의 제조 방법
|
|
EP3365334B1
(en)
*
|
2015-10-21 |
2024-07-17 |
Otsuka Pharmaceutical Co., Ltd. |
Benzolactam compounds as protein kinase inhibitors
|
|
HUE061437T2
(hu)
|
2015-10-23 |
2023-06-28 |
Navitor Pharm Inc |
A Sestrin-GATOR2 kölcsönhatás modulátorai és ezek alkalmazásai
|
|
US11370792B2
(en)
|
2015-12-14 |
2022-06-28 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of MTHFD2 and uses thereof
|
|
WO2017103611A1
(en)
|
2015-12-16 |
2017-06-22 |
Redx Pharma Plc |
Compounds useful as kinase inhibitors
|
|
CN107021963A
(zh)
|
2016-01-29 |
2017-08-08 |
北京诺诚健华医药科技有限公司 |
吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
|
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
LT3426243T
(lt)
|
2016-03-09 |
2021-08-10 |
Raze Therapeutics, Inc. |
3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas
|
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
CN105968056A
(zh)
*
|
2016-05-28 |
2016-09-28 |
大连医科大学 |
二芳基嘧啶类化合物，组合物及用途
|
|
WO2017223243A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
CN109640988A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
CA3033827A1
(en)
|
2016-08-16 |
2018-02-22 |
Beigene, Ltd. |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
|
|
PT3500299T
(pt)
|
2016-08-19 |
2024-02-21 |
Beigene Switzerland Gmbh |
Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
|
|
CN106316886A
(zh)
*
|
2016-08-24 |
2017-01-11 |
泰州精英化成医药科技有限公司 |
顺式‑3‑（叔丁氧羰基氨基）环己烷甲酸的制备方法
|
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
|
EP3848370B1
(en)
|
2016-10-14 |
2025-05-07 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
CN107973754B
(zh)
*
|
2016-10-25 |
2020-04-14 |
清华大学 |
一种小分子抑制剂及其制备方法与其在多发性骨髓瘤治疗中的应用
|
|
JP2020023441A
(ja)
*
|
2016-11-02 |
2020-02-13 |
国立大学法人九州大学 |
Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物
|
|
AU2017355544A1
(en)
|
2016-11-03 |
2019-05-16 |
Juno Therapeutics, Inc. |
Combination therapy of a T cell therapy and a BTK inhibitor
|
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
|
EP4035659A1
(en)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
WO2018115203A1
(en)
|
2016-12-23 |
2018-06-28 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
|
CN106632273A
(zh)
*
|
2016-12-29 |
2017-05-10 |
大连医科大学 |
含唑杂环的嘧啶类化合物，组合物及其用途
|
|
EP3565638B8
(en)
|
2017-01-06 |
2024-04-10 |
BicycleRD Limited |
Bicycle conjugate for treating cancer
|
|
CN108329274B
(zh)
*
|
2017-01-13 |
2021-09-03 |
正大天晴药业集团股份有限公司 |
布鲁顿酪氨酸激酶抑制剂
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
CN108498477A
(zh)
*
|
2017-02-27 |
2018-09-07 |
江苏奥赛康药业股份有限公司 |
一种2-氨基嘧啶类化合物的药用组合物及其制备方法
|
|
JP7160824B2
(ja)
|
2017-03-08 |
2022-10-25 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤、使用およびその製造のための方法
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
AU2017408099A1
(en)
|
2017-04-07 |
2019-11-07 |
ACEA Therapeutics, Inc. |
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
|
|
JP7145874B2
(ja)
|
2017-04-14 |
2022-10-03 |
バイオジェン・エムエイ・インコーポレイテッド |
ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体
|
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
|
WO2018197893A1
(en)
|
2017-04-27 |
2018-11-01 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3641772B1
(en)
|
2017-06-22 |
2023-08-02 |
Celgene Corporation |
Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
|
|
TW202515616A
(zh)
|
2017-06-26 |
2025-04-16 |
英屬開曼群島商百濟神州有限公司 |
抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
|
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
バイスクルアールディー・リミテッド |
検出可能部分を持つ二環式ペプチドリガンドおよびその使用
|
|
KR102717819B1
(ko)
|
2017-07-28 |
2024-10-14 |
다케다 야쿠힌 고교 가부시키가이샤 |
Tyk2 억제제 및 이의 용도
|
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
|
WO2019034868A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
WO2019034153A1
(zh)
*
|
2017-08-18 |
2019-02-21 |
北京韩美药品有限公司 |
一种化合物，其药物组合物及其用途及应用
|
|
EP3675838A4
(en)
|
2017-08-29 |
2021-04-21 |
PureTech LYT, Inc. |
LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
KR102383561B1
(ko)
*
|
2017-09-07 |
2022-04-06 |
한국화학연구원 |
테트라히드로이소퀴놀린기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
JP7167146B2
(ja)
|
2017-11-06 |
2022-11-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｈｐｋ１阻害剤として有用なイソフラノン化合物
|
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
KR20200116481A
(ko)
|
2018-01-29 |
2020-10-12 |
메르크 파텐트 게엠베하 |
Gcn2 억제제 및 이의 용도
|
|
EP3746071A4
(en)
|
2018-01-29 |
2021-09-01 |
Merck Patent GmbH |
GCN2 INHIBITORS AND THEIR USES
|
|
TWI798334B
(zh)
|
2018-01-31 |
2023-04-11 |
大陸商迪哲（江蘇）醫藥股份有限公司 |
Ｅｒｂｂ／ｂｔｋ抑制劑
|
|
JP2021514953A
(ja)
|
2018-02-23 |
2021-06-17 |
バイスクルテクス・リミテッド |
多量体二環式ペプチドリガンド
|
|
KR20260028873A
(ko)
|
2018-02-27 |
2026-03-04 |
아텍스 바이오파마 인코포레이티드 |
Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체
|
|
CN112533602A
(zh)
|
2018-04-05 |
2021-03-19 |
大日本住友制药肿瘤公司 |
Axl激酶抑制剂及其用途
|
|
ES2919572T3
(es)
|
2018-04-24 |
2022-07-27 |
Merck Patent Gmbh |
Compuestos antiproliferación y usos de los mismos
|
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
|
MD3784664T2
(ro)
|
2018-04-26 |
2025-06-30 |
Pfizer |
Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline
|
|
US20210121466A1
(en)
|
2018-05-03 |
2021-04-29 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
IL314362A
(en)
|
2018-06-15 |
2024-09-01 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and their uses
|
|
IL279489B2
(en)
|
2018-06-22 |
2025-10-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
JP7619951B2
(ja)
|
2018-10-15 |
2025-01-22 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
WO2020084305A1
(en)
|
2018-10-23 |
2020-04-30 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
CN109608444B
(zh)
*
|
2018-11-27 |
2022-02-11 |
中国药科大学 |
含异吲哚啉酮的erk抑制剂及其制备方法与用途
|
|
JP7530360B2
(ja)
|
2018-11-30 |
2024-08-07 |
武田薬品工業株式会社 |
Ｔｙｋ２阻害剤およびその使用
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
US12551567B2
(en)
|
2018-12-21 |
2026-02-17 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
JP2022514618A
(ja)
|
2018-12-21 |
2022-02-14 |
バイスクルテクス・リミテッド |
Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
|
|
CN120865208A
(zh)
|
2019-01-23 |
2025-10-31 |
武田药品工业株式会社 |
Tyk2抑制剂和其用途
|
|
CN109776495A
(zh)
*
|
2019-01-31 |
2019-05-21 |
李佳睿 |
抗肿瘤化合物及其制备方法与用途
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
WO2020168197A1
(en)
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
|
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
KR20210144844A
(ko)
|
2019-03-29 |
2021-11-30 |
아스트라제네카 아베 |
비-소세포 폐암의 치료에 사용하기 위한 오시머티닙
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
TWI875749B
(zh)
|
2019-04-05 |
2025-03-11 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
|
WO2020223558A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
Tricyclic amine compounds as cdk2 inhibitors
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
EP3966207B1
(en)
|
2019-05-10 |
2023-11-01 |
Deciphera Pharmaceuticals, LLC |
Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
MX2021013662A
(es)
|
2019-05-10 |
2022-03-11 |
Deciphera Pharmaceuticals Llc |
Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
|
|
WO2020243423A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2020249001A1
(zh)
|
2019-06-10 |
2020-12-17 |
百济神州瑞士有限责任公司 |
一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
IL325201A
(en)
|
2019-06-17 |
2026-02-01 |
Deciphera Pharmaceuticals Llc |
Aminopyrimidine amide autophagy inhibitors and methods of using them
|
|
WO2020257495A1
(en)
*
|
2019-06-18 |
2020-12-24 |
Purdue Research Foundation |
Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CN110305140B
(zh)
*
|
2019-07-30 |
2020-08-04 |
上海勋和医药科技有限公司 |
二氢吡咯并嘧啶类选择性jak2抑制剂
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
TW202115024A
(zh)
|
2019-08-14 |
2021-04-16 |
美商英塞特公司 |
作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
|
|
JP7842684B2
(ja)
|
2019-09-11 |
2026-04-08 |
ビンシア・バイオサイエンシーズ・インコーポレイテッド |
Ｕｓｐ３０阻害剤及びその使用
|
|
CN114945366B
(zh)
|
2019-09-13 |
2025-01-07 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
CN112574207B
(zh)
*
|
2019-09-30 |
2023-04-11 |
南京药石科技股份有限公司 |
Erk1/2蛋白激酶抑制剂及其用途
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2020364007A1
(en)
|
2019-10-11 |
2022-04-28 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP2023500352A
(ja)
*
|
2019-11-08 |
2023-01-05 |
深▲セン▼微芯生物科技股▲フン▼有限公司 |
移植片対宿主病を予防又は治療するための化合物
|
|
CN112933049B
(zh)
*
|
2019-11-26 |
2024-02-06 |
深圳微芯生物科技股份有限公司 |
含无定型态芳杂环化合物的组合物、其制备方法及用途
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
KR20220128345A
(ko)
|
2019-12-05 |
2022-09-20 |
아나쿠리아 테라퓨틱스, 인코포레이티드 |
라파마이신 유사체 및 이의 용도
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US11685727B2
(en)
|
2019-12-20 |
2023-06-27 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
MX2022007265A
(es)
|
2019-12-20 |
2022-09-09 |
Nuevolution As |
Compuestos activos frente a receptores nucleares.
|
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
WO2021138391A1
(en)
|
2019-12-30 |
2021-07-08 |
Tyra Biosciences, Inc. |
Indazole compounds
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN111620852B
(zh)
*
|
2020-01-19 |
2023-05-09 |
镇江植生源农业科技有限公司 |
一种5-氯-嘧啶-2,4-二胺类化合物及其制备方法和应用
|
|
CN115348864A
(zh)
|
2020-02-05 |
2022-11-15 |
纯技术Lyt股份有限公司 |
神经甾体的脂质前药
|
|
KR20220153582A
(ko)
|
2020-02-14 |
2022-11-18 |
솔크 인스티튜트 포 바이올로지칼 스터디즈 |
마크로시클릭 ulk1/2 억제제
|
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
US12528785B2
(en)
|
2020-03-19 |
2026-01-20 |
Kymera Therapeutics, Inc. |
MDM2 degraders and uses thereof
|
|
CA3174176A1
(en)
|
2020-03-31 |
2021-10-07 |
Sanne Schroder Glad |
Compounds active towards nuclear receptors
|
|
EP4126874A1
(en)
|
2020-03-31 |
2023-02-08 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
BR112022020291A2
(pt)
|
2020-04-07 |
2022-12-06 |
Mitobridge Inc |
Inibidores de cd38
|
|
WO2021247897A1
(en)
|
2020-06-03 |
2021-12-09 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN111646978B
(zh)
*
|
2020-06-11 |
2021-12-21 |
浙江大学 |
N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用
|
|
US20230257350A1
(en)
*
|
2020-07-02 |
2023-08-17 |
The Cleveland Clinic Foundation |
Compounds and methods of promoting oligodendrocyte precursor differentiation
|
|
IL299695A
(en)
|
2020-07-09 |
2023-03-01 |
Usher Iii Initiative Inc |
Treatment of cancer, inflammatory diseases and autoimmune diseases
|
|
IL300248A
(en)
|
2020-08-03 |
2023-03-01 |
Bicycletx Ltd |
peptide-based linkers
|
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
|
JP7801084B2
(ja)
*
|
2020-09-22 |
2026-01-16 |
ベイジーン リミテッド |
Ｅｇｆｒ阻害剤としてのインドリン化合物及び誘導体
|
|
WO2022072632A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Scorpion Therapeutics, Inc. |
Bicyclic compounds for use in the treatment cancer
|
|
US12331046B2
(en)
|
2020-10-23 |
2025-06-17 |
Nimbus Clotho, Inc. |
CTPS1 inhibitors and uses thereof
|
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
PH12023500015A1
(en)
|
2020-12-30 |
2024-03-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP4288427A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
CN117120090A
(zh)
|
2021-02-12 |
2023-11-24 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
EP4301756A4
(en)
|
2021-03-05 |
2025-02-26 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
CN115160319B
(zh)
*
|
2021-04-01 |
2023-12-26 |
西安新通药物研究股份有限公司 |
含1,3-苯并二氧戊环结构的化合物及其制备方法与用途
|
|
US20240216330A1
(en)
|
2021-04-02 |
2024-07-04 |
Biogen Ma Inc. |
Combination treatment methods of multiple sclerosis
|
|
AU2022256074A1
(en)
|
2021-04-09 |
2023-11-02 |
Nimbus Clio, Inc. |
Cbl-b modulators and uses thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
JP2024514879A
(ja)
|
2021-04-16 |
2024-04-03 |
イケナ オンコロジー， インコーポレイテッド |
Ｍｅｋ阻害剤及びその使用
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
JP2024534127A
(ja)
|
2021-08-25 |
2024-09-18 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|
|
US12157732B2
(en)
|
2021-08-25 |
2024-12-03 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
US12187744B2
(en)
|
2021-10-29 |
2025-01-07 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and synthesis thereof
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
US12233056B2
(en)
|
2022-04-06 |
2025-02-25 |
Syntara Limited |
Lysyl oxidase inhibitors for treating myeloid malignancies
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
IL316768A
(en)
|
2022-05-25 |
2025-01-01 |
Ikena Oncology Inc |
MEK inhibitors and their uses
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
JP2025527247A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
|
|
CN120051456A
(zh)
|
2022-08-02 |
2025-05-27 |
里米诺生物科学有限公司 |
取代的吡啶酮gpr84拮抗剂及其用途
|
|
IL318575A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
|
|
CN115448906B
(zh)
*
|
2022-09-26 |
2024-04-02 |
深圳大学 |
一种2-苯胺基嘧啶类衍生物及其制备方法与应用
|
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
IL321486A
(en)
|
2023-06-23 |
2025-08-01 |
Kymera Therapeutics Inc |
Iraqi joints and their uses
|
|
WO2025062372A1
(en)
|
2023-09-21 |
2025-03-27 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
|
TW202515850A
(zh)
*
|
2023-09-22 |
2025-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
雜芳基類化合物、其製備方法及其在醫藥上的應用
|
|
CN119707835A
(zh)
*
|
2024-11-25 |
2025-03-28 |
沈阳药科大学 |
2-氨基嘧啶-5-甲酰胺类化合物及用于制备治疗和/或预防癌症药物中的用途
|